Ropes & Gray advised ImmunoGen, a leader in the field of antibody-drug conjugates for cancer treatment, in a clinical collaboration with Gilead Sciences to evaluate the safety and anti-leukemia activity of ImmunoGen’s ADC, pivekimab sunirine, in combination with Gilead’s drug magrolimab, a potential first-in-class investigational inhibitor for patients with relapsed or refractory positive acute myeloid leukemia blood cancer. The clinical collaboration was announced on December 9. Financial terms were not disclosed.
Expected to initiate in 2023, the collaboration will create a new cohort in ImmunoGen’s “802 study,” a Phase 1b/2 clinical trial to evaluate pivekimab in combination with magrolimab in patients with positive AML.
The Ropes & Gray team was led by life sciences partner Abigail Gregor and included health care partner David Peloquin and corporate associate Mike Tentilucci.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.